AIM
PTLA

Acrospire Investment Management’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Acrospire Investment Management’s Portfolio PTLA Stock Details PTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-700
Closed -$27K – 2701
2017
Q1 		$27K Buy
+700
New +$22.3K 0.02% 1436

Other funds holding PTLA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Acrospire Investment Management's PTLA Position: Q2 2017 in Review

Acrospire Investment Management sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q2 2017, closing a stake of 700 shares — an estimated $27K sold.

Acrospire Investment Management first reported a position in PTLA in Q1 2017 and held it in 1 quarter. The position peaked at $27K in Q1 2017. 206 funds tracked by Wall St. Rank hold PTLA as of Q2 2017.

  • Acrospire Investment Management reported no remaining Portola Pharmaceuticals, Inc. position as of Q2 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 700 Portola Pharmaceuticals, Inc. shares in Q2 2017, an estimated $27K.
  • Acrospire Investment Management first reported a position in Portola Pharmaceuticals, Inc. in Q1 2017 and held it in 1 quarter.
  • Acrospire Investment Management's Portola Pharmaceuticals, Inc. position peaked at $27K in Q1 2017.
  • 206 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q2 2017.

Based on Acrospire Investment Management's 13F filing for Q2 2017, filed 11 Aug 2017.